What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Prostate cancer
His primary areas of study are Prostate cancer, Internal medicine, Oncology, Cancer and Surgery.
The concepts of his Prostate cancer study are interwoven with issues in Cancer research, Chemotherapy, Docetaxel and Urology.
His Internal medicine study frequently involves adjacent topics like Endocrinology.
His studies deal with areas such as Odds ratio, Survival analysis, Adverse effect and Proportional hazards model as well as Oncology.
As part of one scientific family, he deals mainly with the area of Surgery, narrowing it down to issues related to the Placebo, and often Randomization, Maintenance therapy, Gastroenterology, Ipilimumab and Asymptomatic.
His work deals with themes such as Interim analysis and Darolutamide, which intersect with Enzalutamide.
His most cited work include:
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy (1679 citations)
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (1635 citations)
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer (1587 citations)
What are the main themes of his work throughout his whole career to date?
Tomasz M. Beer mostly deals with Prostate cancer, Internal medicine, Oncology, Docetaxel and Enzalutamide.
His Prostate cancer research is multidisciplinary, incorporating perspectives in Prostate and Surgery, Chemotherapy.
Tomasz M. Beer combines subjects such as Adverse effect and Urology with his study of Surgery.
His research in Internal medicine intersects with topics in Placebo and Endocrinology.
In Oncology, he works on issues like Prednisone, which are connected to Abiraterone acetate.
His study explores the link between Docetaxel and topics such as Calcitriol that cross with problems in Pharmacology.
He most often published in these fields:
- Prostate cancer (78.44%)
- Internal medicine (70.89%)
- Oncology (60.00%)
What were the highlights of his more recent work (between 2016-2021)?
- Prostate cancer (78.44%)
- Internal medicine (70.89%)
- Oncology (60.00%)
In recent papers he was focusing on the following fields of study:
Tomasz M. Beer focuses on Prostate cancer, Internal medicine, Oncology, Enzalutamide and Castration resistant.
His Prostate cancer research includes themes of Placebo, Cancer research and Clinical trial.
His studies in Hazard ratio, Clinical endpoint, Cancer, Androgen deprivation therapy and Progression-free survival are all subfields of Internal medicine research.
The various areas that Tomasz M. Beer examines in his Oncology study include Docetaxel, Chemotherapy, Phases of clinical research, Biopsy and Disease.
Tomasz M. Beer focuses mostly in the field of Enzalutamide, narrowing it down to matters related to Apalutamide and, in some cases, Darolutamide.
His Castration resistant research includes elements of Poor prognosis, Bicalutamide and Chemotherapy naive.
Between 2016 and 2021, his most popular works were:
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 (333 citations)
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer (306 citations)
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. (223 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Prostate cancer
Tomasz M. Beer mainly investigates Prostate cancer, Internal medicine, Oncology, Enzalutamide and Cancer research.
Prostate cancer is a primary field of his research addressed under Cancer.
His Internal medicine research is multidisciplinary, relying on both Placebo and PTEN.
His Oncology research incorporates themes from Clinical endpoint, Randomized controlled trial, Phases of clinical research and Clinical trial.
His Enzalutamide research incorporates elements of Pembrolizumab, Androgen, Adverse effect and Docetaxel.
His Cancer research study combines topics in areas such as Exome sequencing, Mutation, Structural variation, Prostate and Carcinogenesis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
